A VLP-based platform for Vaccine Discovery

基于 VLP 的疫苗发现平台

基本信息

项目摘要

DESCRIPTION (provided by applicant): Virus-like particles (VLPs) make excellent platforms for displaying antigens in a highly immunogenic format. However, to date, VLPs have not been used to identify antigenic epitopes. In contrast, filamentous phage display is a useful technique for identification of antigenic epitopes, but these phage make poor immunogens. In this proposal, we describe a new platform based on VLPs of the RNA bacteriophage MS2, which serves both as a substrate for epitope affinity-selection and directly as an immunogen. Because affinity-selection and immunogen presentation are conducted on a single structural platform, we expect that selected epitopes will be more faithful molecular mimics of the target epitope. As a test of this idea, we use our system to select antigenic epitopes using an MS2 phage library. This library will be screened using monoclonal antibodies (mAbs) that recognize a well-defined linear epitope and a complex conformational epitope. In AIM 1, we will develop techniques to optimize the selection of epitopes with high affinity for the selecting antibodies. In AIM 2, we will assess the affinities of selected recombinant VLPs, measure their immunogenicity, and determine whether these VLPs, which are selected with mAbs, elicit similar antibody responses. We believe that this technology represents a new way to select epitopes in a highly immunogenic context that mimics their native conformation, and will have significant implications for vaccine development. Successful completion of these studies will lay the groundwork for selections of potential vaccines using, say, broadly neutralizing mAbs against infectious disease targets of interest (mAbs targeting Hepatitis C virus, Human Papillomavirus, & HIV are examples, but there are many other potential targets). Moreover, since we have shown that VLP-based immunogens can effectively elicit antibody responses to self-antigens, we could also use this technique to develop vaccine alternatives to therapeutic mAbs used to treat chronic diseases. PUBLIC HEALTH RELEVANCE: In this project, we will use a new phage display system, based on virus-like particles (VLPs), for vaccine discovery.
描述(由申请人提供):病毒样颗粒(VLP)是以高免疫原性形式展示抗原的极好平台。然而,迄今为止,VLP尚未用于鉴定抗原表位。相反,丝状噬菌体展示是鉴定抗原表位的有用技术,但这些噬菌体产生差的免疫原。在这个建议中,我们描述了一个新的平台的基础上的RNA噬菌体MS2,它既作为一个基板的表位亲和选择,并直接作为一种免疫原的VLPs。由于亲和选择和免疫原呈递在单一结构平台上进行,我们预期所选表位将是靶表位的更忠实的分子模拟物。作为这个想法的测试,我们使用我们的系统来选择抗原表位使用MS2噬菌体文库。将使用识别明确定义的线性表位和复杂构象表位的单克隆抗体(mAb)筛选该文库。在AIM 1中,我们将开发技术来优化选择抗体的高亲和力表位的选择。在AIM 2中,我们将评估所选重组VLP的亲和力,测量其免疫原性,并确定这些用mAb选择的VLP是否引发类似的抗体应答。 我们相信,这项技术代表了一种新的方式来选择表位在一个高度免疫原性的情况下,模仿其天然构象,并将有重大意义的疫苗开发。这些研究的成功完成将为选择潜在的疫苗奠定基础,例如,针对感兴趣的传染病靶标的广泛中和mAb(靶向丙型肝炎病毒,人类乳头瘤病毒和HIV的mAb是例子,但还有许多其他潜在的靶标)。此外,由于我们已经表明基于VLP的免疫原可以有效地引发对自身抗原的抗体应答,我们还可以使用这种技术来开发用于治疗慢性疾病的治疗性mAb的疫苗替代品。 公共卫生相关性:在这个项目中,我们将使用一种新的噬菌体展示系统,基于病毒样颗粒(VLP),用于疫苗发现。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Bryce C Chackerian其他文献

Bryce C Chackerian的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Bryce C Chackerian', 18)}}的其他基金

Virus-like Particle based malaria vaccines targeting vulnerable epitopes in the circumsporozoite protein
针对环子孢子蛋白中脆弱表位的基于病毒样颗粒的疟疾疫苗
  • 批准号:
    10606388
  • 财政年份:
    2022
  • 资助金额:
    $ 29.9万
  • 项目类别:
Bacteriophage virus-like particle vaccines for fentanyl and heroin overdose
用于治疗芬太尼和海洛因过量的噬菌体病毒样颗粒疫苗
  • 批准号:
    10157937
  • 财政年份:
    2021
  • 资助金额:
    $ 29.9万
  • 项目类别:
Peptide-VLP Vaccines
肽-VLP疫苗
  • 批准号:
    10588246
  • 财政年份:
    2019
  • 资助金额:
    $ 29.9万
  • 项目类别:
Peptide-VLP Vaccines
肽-VLP疫苗
  • 批准号:
    10362597
  • 财政年份:
    2019
  • 资助金额:
    $ 29.9万
  • 项目类别:
Innate-like BCR activity as a template for universal vaccination against influenza virus
类先天 BCR 活性作为流感病毒通用疫苗接种的模板
  • 批准号:
    10402386
  • 财政年份:
    2018
  • 资助金额:
    $ 29.9万
  • 项目类别:
Innate-like BCR activity as a template for universal vaccination against influenza virus
类先天 BCR 活性作为流感病毒通用疫苗接种的模板
  • 批准号:
    10163789
  • 财政年份:
    2018
  • 资助金额:
    $ 29.9万
  • 项目类别:
A nanoparticle-based vaccine targeting PCSK9
一种针对 PCSK9 的纳米颗粒疫苗
  • 批准号:
    9413459
  • 财政年份:
    2017
  • 资助金额:
    $ 29.9万
  • 项目类别:
EVALUATION OF A CCR5 VACCINE FOR HIV INFECTION IN THE SIV/MACAQUE MODEL
在 SIV/猕猴模型中评估 CCR5 疫苗对 HIV 感染的影响
  • 批准号:
    8357323
  • 财政年份:
    2011
  • 资助金额:
    $ 29.9万
  • 项目类别:
A VLP-based platform for Vaccine Discovery
基于 VLP 的疫苗发现平台
  • 批准号:
    8511548
  • 财政年份:
    2010
  • 资助金额:
    $ 29.9万
  • 项目类别:
EVALUATION OF A CCR5 VACCINE FOR HIV INFECTION IN THE SIV/MACAQUE MODEL
在 SIV/猕猴模型中评估 CCR5 疫苗对 HIV 感染的影响
  • 批准号:
    8172604
  • 财政年份:
    2010
  • 资助金额:
    $ 29.9万
  • 项目类别:

相似海外基金

University of Aberdeen and Vertebrate Antibodies Limited KTP 23_24 R1
阿伯丁大学和脊椎动物抗体有限公司 KTP 23_24 R1
  • 批准号:
    10073243
  • 财政年份:
    2024
  • 资助金额:
    $ 29.9万
  • 项目类别:
    Knowledge Transfer Partnership
Role of Natural Antibodies and B1 cells in Fibroproliferative Lung Disease
天然抗体和 B1 细胞在纤维增生性肺病中的作用
  • 批准号:
    10752129
  • 财政年份:
    2024
  • 资助金额:
    $ 29.9万
  • 项目类别:
CAREER: Next-generation protease inhibitor discovery with chemically diversified antibodies
职业:利用化学多样化的抗体发现下一代蛋白酶抑制剂
  • 批准号:
    2339201
  • 财政年份:
    2024
  • 资助金额:
    $ 29.9万
  • 项目类别:
    Continuing Grant
Isolation and characterisation of monoclonal antibodies for the treatment or prevention of antibiotic resistant Acinetobacter baumannii infections
用于治疗或预防抗生素耐药鲍曼不动杆菌感染的单克隆抗体的分离和表征
  • 批准号:
    MR/Y008693/1
  • 财政年份:
    2024
  • 资助金额:
    $ 29.9万
  • 项目类别:
    Research Grant
Developing first-in-class aggregation-specific antibodies for a severe genetic neurological disease
开发针对严重遗传神经系统疾病的一流聚集特异性抗体
  • 批准号:
    10076445
  • 财政年份:
    2023
  • 资助金额:
    $ 29.9万
  • 项目类别:
    Grant for R&D
Discovery of novel nodal antibodies in the central nervous system demyelinating diseases and elucidation of the mechanisms through an optic nerve demyelination model
发现中枢神经系统脱髓鞘疾病中的新型节点抗体并通过视神经脱髓鞘模型阐明其机制
  • 批准号:
    23K14783
  • 财政年份:
    2023
  • 资助金额:
    $ 29.9万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms controlling the physicochemical properties and functions of supercharged antibodies and development of their applications
阐明控制超电荷抗体的理化性质和功能的机制及其应用开发
  • 批准号:
    23KJ0394
  • 财政年份:
    2023
  • 资助金额:
    $ 29.9万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
Role of antibodies in hepatitis E virus infection
抗体在戊型肝炎病毒感染中的作用
  • 批准号:
    10639161
  • 财政年份:
    2023
  • 资助金额:
    $ 29.9万
  • 项目类别:
Defining the protective or pathologic role of antibodies in Post-Ebola Syndrome
定义抗体在埃博拉后综合症中的保护或病理作用
  • 批准号:
    10752441
  • 财政年份:
    2023
  • 资助金额:
    $ 29.9万
  • 项目类别:
Human CMV monoclonal antibodies as therapeutics to inhibit virus infection and dissemination
人 CMV 单克隆抗体作为抑制病毒感染和传播的治疗药物
  • 批准号:
    10867639
  • 财政年份:
    2023
  • 资助金额:
    $ 29.9万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了